What's new? Log in Free sign up

Sol-Gel Technologies (SLGL) News and press releases

Company Profile

News

From Benzinga Pro

Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.

Raymond James Maintains Strong Buy on Sol-Gel Technologies, Lowers Price Target to $10

News, Price Target, Analyst Ratings

Raymond James analyst Elliot Wilbur maintains Sol-Gel Technologies (NASDAQ:SLGL) with a Strong Buy and lowers the price target from $13 to $10.

HC Wainwright & Co. Reiterates Buy on Sol-Gel Technologies, Maintains $19 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and maintains $19 price target.

Press releases

From Benzinga Pro

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

News, Press Releases

NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline,

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Earnings, Press Releases

Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

Markets, Press Releases

NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL) ("Sol-Gel" or the "Company"), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Press Releases, General

Patidegib, an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDAPhase 3 study expected to

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.